AlphaValue Corporate Services
This research has been commissioned and paid for by the company and does therefore not constitute an inducement caught by the prohibition under MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Target
Upside 489%
Price (€) 1.9
Market Cap (€M) 69.4
Worth Knowing

Zeneo, an automatic, single-use needle-free injection device was originally developed within Laboratoires Fournier in its « drug delivery » division, together with SNPE (Société Nationale des Poudres et Explosifs, which is a shareholder of Crossject). In 2001, the technology was sold to the newly-created Crossject. GSK was originally the main partner of Crossject, with a view to developing a solution for its vaccines. This market was ultimately considered as too risky in terms of investment needs, low margins and the high volumes required and so Crossject was restructured in 2011-13, with a change in the group’s strategy: the goal of Crossject is no longer to sell a device to the Big Pharmas to market their own chemical entities, but to provide the market with its own pre-filled devices, on the basis of New Therapeutic Entities, using a known drug with an innovative delivery system. An industrial partnership has also been signed with Cenexi in 2016 (aseptic filling and final packaging). Today, the Zeneo device is protected by over 400 patents in countries covering 80% of the global market (including the US, Europe and Japan) and valid until 2036.

Shareholders
Name% owned Of which
% voting rights
Of which
% free to float
Gemmes Ventures 24.5%30.0%0.00%
Vester Finance 14.8%11.0%14.8%
SNPE 2.80%2.80%0.00%
Other 2.42%2.42%0.00%
IDEB 0.65%0.65%0.00%
Treasury Shares 0.65%0.65%0.00%
Apparent free float  69.0%
Changes to Shareholding : 05/06/2024.
Concepts
Business Concepts
  • Government driven business
Investment Concepts
  • Growth
Exclusion Concepts